Author/Editor		Strojan, Primož; Budihna, Marjan; Šmid, Lojze; Svetic, Branka; Vrhovec, Ivan; Kos, Janko; Škrk, Janez
Title		Cathepsin H in squamous cell carcinoma of the head and neck
Translated title		Katepsin H pri ploščatoceličnem karcinomu glave in vratu
Type		članek
Source		Radiol Oncol
Vol. and No.		Letnik 33, št. 2
Publication year		1999
Volume		str. 143-51
Language		eng
Abstract		Purpose. To estimate a prognostic value of cathepsin H (CH) in squamous cell carcinoma of the head and neck (SCCHN). Materials and methods. CH concentration was measured using a quantitative immunosorbent assay (ELISA; KRKA d.d., Novo mesto, Slovenia) in serum samples from 35 patients, obtained at surgery (Serum no. 1) and 7-407 days (median, 55 days) after therapy (Serum no. 2). As control, CH concentration as measured in sera from 30 healthy volunteers was used from the study of Kos et al. (Clin Cancer Res, 1997). The prognostic significance of serum concentration of CH was compared with that of its tissue concentration from the study of Budihna et al. (Biol Chem Hoppe-Seyler,1996), and for this purpose the follow-up of patients from the latter report was updated. Results. A significantly elevated concentration of CH was measured in Serum no.1 as compared to Serum no. 2. (8.9 vs. 8.0 ng/mls, P=0.04) or the sera from healthy volunteers (8.9 vs. 4.9 ng/mls, P<0.0001). The CH concentration in Serum no.1 appeared to be grade dependant (G1+2 vs. G3, 9.1 vs. 5.0 ng/mls, P=0.06); no correlation was observed with other established prognostic factors or the presence of subsequent recurrence/dissemination of the disease. The time of Serum no 2 collection did not influence the CH concentration these samples. There was a trend towards a better prognosis with increasing levels of CH in Serum no. 1 in both the analysis of disease free survival (DFS) and disease-specific survival (DSS). The maximal differences in survival rates between patients with low and high CH levels were calculated at rut-off concentration 10.7 ng/mls (DFS: 60 vs. 89%, P=0.13; DSS: 65 vs. 86%, P=0.25). The results of tissue concentration of CH were equivocal, with the maximal difference between low and high CH groups at cut-off concentration 720 ng/mgp (DFS:14 vs. 48 %, P=0.04; DSS: 23 vs. 60 %, P=0.27). (Abstract truncated at 2000 characters).
Summary		Izhodišča. Oceniti napovedno vrednost katepsina H (KH) pri bolnikih s ploščatoceličnim karcinomu glave in vratu (PCKGV). Material in metode. Koncentracijo KH smo izmerili v vzorcih seruma 35 bolnikov, odvzetih ob operaciji (serum št.1) in 7 - 407 dni (mediana 55 dni) po zdravljenju (serum št.2). Uporabljali smo kvantitativni encimskoimunski test (ELISA; KRKA d.d., Novo mesto, Slovenija). Koncentracija KH, ki so jo v serumu 30 zdravih prostovoljcev izmerili Kos in sod. (Clin Cancer Res, 1997), je služila kot kontrola. Napovedno vrednost serumske koncentracije KH smo primerjali z izsledki raziskave Budihne in sod. (Biol Chem Hoppe-Seyler, 1996) o napovedni vrednosti tkivne koncentracije KH. Za to priložnost je bilo preživetje bolnikov iz omenjenega poročila ponovno evaluirano. Rezultati. V serumu št.1 smo izmerili statistično značilno višjo koncentracijo KH kot v serumu št.2 (8.9 vs. 8.0 ng/mls, P=0.04) oz. v serumu zdravih prostovoljcev (8.9 vs. 4.9 ng/mls, P<0.0001). Koncentracija KH v serumu št.1 je bila statistično mejno odvisna od histopatološkega gradusa (G1+2 vs. G3, 9.1 vs.5.0 ng/mls, P=0.06), medtem ko povezanosti z drugimi uveljavljenimi napovednimi kazalci oz. pojavom ponovitve/razsoja bolezni nismo zasledili. Čas vzorčenja seruma št.2 ni vplival na koncentracijo KH v teh vzorcih. Nagnjenost k boljšemu preživetju bolnikov pri višjih koncentracijah KH v serumu št.1 smo opazili tako pri analizi preživetja brez znakov bolezni (PBB) kot tudi pri analizi za bolezen specifičnega preživetja (BSP). Največja razlika v deležu preživelih med bolniki z nizko oz. visoko vsebnostjo KH je bila zabeležena pri razmejitveni koncentraciji 10.7 ng/mls (PBB: 60 vs. 89%, P=0.13; BSP: 65 vs. 86%, P=0.25). Rezultati, ki se nanašajo na tkivne koncentracije KH so istosmiselni, pri čemer smo največjo razliko med skupinama z nizko oz. visoko koncentracijo KH izračunali pri razmejitveni koncentraciji 720 ng/mgp (PBB:14 vs. 48%, P=0. (Izvleček skrajšan na 2000 znakov).
Descriptors		HEAD AND NECK NEOPLASMS CARCINOMA, SQUAMOUS CELL CATHEPSINS PROGNOSIS NEOPLASM STAGING SURVIVAL ANALYSIS